Manufacturers

It’s Just…So…Cool – Don’t miss your opportunity for JSC!

Manufacturers

Apples to apples, or apples to oranges? Comparing the Inflation Reduction Act to drug-pricing programs in other countries

Manufacturers

Podcast: How 2023 will shape the US Biosimilar space for 2024 and beyond

Manufacturers

Cost and resource burden of coverage with evidence development

Manufacturers

Does the EU HTAR really put patients at the center?

Manufacturers

The more things change, the more they stay the same? Reviewing ICER's revised value assessment framework

Manufacturers

Gauge the impact: What does the striking down of a federal copay accumulator regulation mean for patients and copay programs?

Manufacturers

First 10 drugs for Medicare price negotiation announced under IRA

Manufacturers

Q&A – Preparing for the EU Joint Clinical Assessment (JCA) process

HTA Quarterly | Fall 2023

Manufacturers

Only 17 months until the implementation of the new EU JCA—Latest developments and remaining uncertainties

Manufacturers

VPAS—Where next?

Manufacturers

Podcast: Collaborative perseverance to bring change to medicine access

Manufacturers

Multistakeholder perspectives on Joint Clinical Assessment in Europe

Pharmacies

3 ways your distributor can help you prepare for DSCSA compliance

Manufacturers

Recap AMCP 2023: Our thought leadership in action

Manufacturers

Answering four key questions about HTA market archetypes

Pharmacies

DSCSA: Are you ready for November 2024?

Physician Practices

Physician fee cuts and policy updates: What's at stake for practices in 2023

Policy updates: From the Inflation Reduction Act to the Enhancing Oncology Model

Manufacturers

Closing the gaps in pre-approval information exchange to accelerate product success and patient access

Manufacturers

Roundtable: Policy and its impact on the pharmaceutical industry

Webinar: Debunking common PIE misperceptions to enhance your PIE strategy and tactics

Manufacturers

Working with government entities to advance access, affordability, and supply chain stability

Manufacturers

Health policy and the political landscape

Podcast: Insulin biosimilars part 2

Podcast: Insulin biosimilars part 1

Affordability is about more than drug prices

Manufacturers

Strategies for addressing copay accumulators: What manufacturers need to know

Manufacturers

Webinar: the growing utilization of copay accumulator programs

Let's Ditch 2020 and Plan for 2021: Election What-Ifs

Health Systems

Biosimilars: Patents, policy, and reimbursement

Manufacturers

Infographic: navigating health policy

Manufacturers

Mind the (Evidence) Gap

Pharmacies

Eight Impact Making Advocacy Tips for Pharmacists

Manufacturers

Managing the Growing Expansion of Copay Accumulators

Manufacturers

Moving Medicare Coverage

Manufacturers

Medicare Part B: Do Providers Choose Treatment Based on Payment?

Manufacturers

Preparing Patients for Open Enrollment

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part Two